Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30% ...

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have suffered ...

About a month ago, I predicted that button locks would be one of the biggest trends in the EDC knife industry this year. While I’m no Nostradamus, I may have been onto something. With the release of ...

Sage is over the hump in its transition to a primary cloud-focused software company. which means operating margins should rise going forward as the benefits of scale kick in.